Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?

Shelby H. Davies; Gabrielle Gold-Von Simson

doi:10.1007/s00246-013-0731-3

Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?

Shelby H. Davies, Gabrielle Gold-Von Simson

Research output: Contribution to journal › Letter

Original language	English (US)
Number of pages	1
Journal	Pediatric Cardiology
Volume	34
Issue number	7
DOIs	https://doi.org/10.1007/s00246-013-0731-3
State	Published - Oct 1 2013
Externally published	Yes

Fingerprint

Mucocutaneous Lymph Node Syndrome

Intravenous Immunoglobulins

Immunologic Factors

Non-Steroidal Anti-Inflammatory Agents

Combination Drug Therapy

Drug Resistance

Tumor Necrosis Factor-alpha

Monoclonal Antibodies

Therapeutics

Infliximab

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Cardiology and Cardiovascular Medicine

Cite this

Davies, S. H., & Gold-Von Simson, G. (2013). Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy? Pediatric Cardiology, 34(7). https://doi.org/10.1007/s00246-013-0731-3

Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy? / Davies, Shelby H.; Gold-Von Simson, Gabrielle.

In: Pediatric Cardiology, Vol. 34, No. 7, 01.10.2013.

Research output: Contribution to journal › Letter

Davies, SH & Gold-Von Simson, G 2013, 'Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?', Pediatric Cardiology, vol. 34, no. 7. https://doi.org/10.1007/s00246-013-0731-3

Davies SH, Gold-Von Simson G. Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy? Pediatric Cardiology. 2013 Oct 1;34(7). https://doi.org/10.1007/s00246-013-0731-3

Davies, Shelby H. ; Gold-Von Simson, Gabrielle. / Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?. In: Pediatric Cardiology. 2013 ; Vol. 34, No. 7.

@article{385517ce99ab4bd39d6cf17799c0c25f,

title = "Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?",

author = "Davies, {Shelby H.} and {Gold-Von Simson}, Gabrielle",

year = "2013",

month = "10",

day = "1",

doi = "10.1007/s00246-013-0731-3",

language = "English (US)",

volume = "34",

journal = "Pediatric Cardiology",

issn = "0172-0643",